Suppr超能文献

慢性肾病患者的健康相关生活质量与血红蛋白水平

Health-related quality of life and hemoglobin levels in chronic kidney disease patients.

作者信息

Finkelstein Fredric O, Story Kenneth, Firanek Catherine, Mendelssohn David, Barre Paul, Takano Tomoko, Soroka Steven, Mujais Salim

机构信息

Hospital of St Raphael, Yale University, New Haven, CT 06511, USA.

出版信息

Clin J Am Soc Nephrol. 2009 Jan;4(1):33-8. doi: 10.2215/CJN.00630208. Epub 2008 Nov 5.

Abstract

BACKGROUND

The relationship between quality of life (QofL) and anemia has been the subject of recent debates; it has been suggested that the QofL changes associated with the treatment of anemia of chronic kidney disease (CKD) or ESRD patients should not be used in making decisions to treat anemia in CKD patients.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study examines the relationship between Kidney Disease Quality of Life (KDQofL) questionnaire domains and hemoglobin (Hgb) levels in 1200 patients with stage 3, 4, and 5 CKD followed in seven centers. QofL measures were compared in a stepwise fashion for hemoglobin levels of <11, 11 to <12, 12 to <13, and > or =13. ANOVA was used to examine the relationship between QofL scores and Hgb level, age, CKD stage, and albumin level; a history of diabetes, congestive heart failure, or myocardial infarction; use of erythropoetic-stimulating agents (ESA); and the interaction of hemoglobin level and ESA.

RESULTS

The results demonstrate that with increasing Hgb levels there is a statistically significant increase in all four physical domains, the energy/vitality domain, and the physical composite score of the SF-36, and the general health score on the kidney disease component of the questionnaire. The most dramatic improvements in these various domains occurred between the <11 and the 11 to 12 group.

CONCLUSIONS

Higher Hgb levels are associated with improved QofL domains of the KDQofL questionnaire. These findings have implications for the care of CKD patients in terms of the initiation of and the Hgb target of ESA therapy.

摘要

背景

生活质量(QofL)与贫血之间的关系一直是近期争论的焦点;有人认为,与慢性肾脏病(CKD)或终末期肾病(ESRD)患者贫血治疗相关的生活质量变化,不应被用于指导CKD患者贫血治疗的决策。

设计、地点、参与者及测量方法:本研究在7个中心对1200例3、4、5期CKD患者进行了研究,探讨了肾脏病生活质量(KDQofL)问卷各领域与血红蛋白(Hgb)水平之间的关系。按照血红蛋白水平<11、11至<12、12至<13以及≥13,逐步比较生活质量指标。采用方差分析来研究生活质量评分与血红蛋白水平、年龄、CKD分期、白蛋白水平、糖尿病史、充血性心力衰竭或心肌梗死史、促红细胞生成素(ESA)的使用以及血红蛋白水平与ESA之间的相互作用。

结果

结果表明,随着血红蛋白水平升高,SF-36问卷的所有四个身体领域、精力/活力领域、身体综合评分以及问卷中肾脏病部分的总体健康评分在统计学上均显著增加。这些不同领域中最显著的改善发生在血红蛋白水平<11组与11至12组之间。

结论

较高的血红蛋白水平与KDQofL问卷中生活质量领域的改善相关。这些发现对于CKD患者ESA治疗的起始及血红蛋白目标具有护理方面的意义。

相似文献

1
Health-related quality of life and hemoglobin levels in chronic kidney disease patients.
Clin J Am Soc Nephrol. 2009 Jan;4(1):33-8. doi: 10.2215/CJN.00630208. Epub 2008 Nov 5.
3
Association of anemia correction with health related quality of life in patients not on dialysis.
Curr Med Res Opin. 2007 Dec;23(12):2997-3008. doi: 10.1185/030079907X242502.
4
An economic evaluation of erythropoiesis-stimulating agents in CKD.
Am J Kidney Dis. 2010 Dec;56(6):1050-61. doi: 10.1053/j.ajkd.2010.07.015. Epub 2010 Oct 8.
5
Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Am J Kidney Dis. 2012 Sep;60(3):371-9. doi: 10.1053/j.ajkd.2012.04.013. Epub 2012 May 26.
6
Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
Clin J Am Soc Nephrol. 2012 Feb;7(2):354-7. doi: 10.2215/CJN.11961111. Epub 2012 Jan 19.
7
Transfusion burden among patients with chronic kidney disease and anemia.
Clin J Am Soc Nephrol. 2010 Apr;5(4):667-72. doi: 10.2215/CJN.06020809. Epub 2010 Mar 18.
8
An expert opinion on the current treatment of anemia in patients with kidney disease.
Expert Opin Pharmacother. 2012 Mar;13(4):495-503. doi: 10.1517/14656566.2012.658369. Epub 2012 Feb 2.
10
Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Clin J Am Soc Nephrol. 2010 Jul;5(7):1340-6. doi: 10.2215/CJN.02830310. Epub 2010 May 6.

引用本文的文献

1
GFR is a Key Determinant of Red Blood Cell Survival in Anemia Associated With Progressive CKD.
Kidney Int Rep. 2024 Dec 21;10(3):730-742. doi: 10.1016/j.ekir.2024.12.023. eCollection 2025 Mar.
2
Conventional and complementary alternative medicine therapies for renal anemia: a literature review.
Front Endocrinol (Lausanne). 2025 Jan 22;15:1342873. doi: 10.3389/fendo.2024.1342873. eCollection 2024.
6
Peritoneal Dialysis of Three-Cuff Catheter Experience in Qassim Province, Saudi Arabia.
Int J Nephrol. 2024 Oct 30;2024:5554703. doi: 10.1155/2024/5554703. eCollection 2024.
7
Outcomes of Early Versus Delayed Anemia Treatment in Nondialysis-Dependent CKD.
Kidney Int Rep. 2024 Apr 15;9(7):2056-2066. doi: 10.1016/j.ekir.2024.04.030. eCollection 2024 Jul.
8
Framework of Guidelines for Management of CKD in Asia.
Kidney Int Rep. 2023 Dec 22;9(4):752-790. doi: 10.1016/j.ekir.2023.12.010. eCollection 2024 Apr.

本文引用的文献

1
Factors associated with health-related quality of life among hemodialysis patients in the DOPPS.
Qual Life Res. 2007 May;16(4):545-57. doi: 10.1007/s11136-006-9143-7. Epub 2007 Feb 8.
2
Correction of anemia with epoetin alfa in chronic kidney disease.
N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485.
3
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
N Engl J Med. 2006 Nov 16;355(20):2071-84. doi: 10.1056/NEJMoa062276.
6
Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
Clin Nephrol. 2004 Jun;61(6):392-405. doi: 10.5414/cnp61392.
8
Validation of the KDQOL-SF: a dialysis-targeted health measure.
Qual Life Res. 2002 Aug;11(5):437-47. doi: 10.1023/a:1015631411960.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验